Sort   by:  
 Page size 
UnknownMulticenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.
Not available
S-EPMC6209089 | biostudies-literature
UnknownAssessment of barriers to pancreatic cancer surveillance in high-risk individuals.
Not available
S-EPMC12511838 | biostudies-literature
UnknownReal-world integration of genomic data into the electronic health record: the PennChart Genomics Initiative.
Not available
S-EPMC8026392 | biostudies-literature
UnknownAssociation of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes.
Not available
S-EPMC7330720 | biostudies-literature
UnknownA randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.
Not available
S-EPMC5618936 | biostudies-literature
UnknownRelationship of established risk factors with breast cancer subtypes.
Not available
S-EPMC8446564 | biostudies-literature
UnknownPilot implementation study of a default genetic referral process for patients with early-onset colorectal cancer.
Not available
S-EPMC11780105 | biostudies-literature
UnknownPatient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial.
Not available
S-EPMC6836724 | biostudies-literature
UnknownClinical Impact of a Rapid Genetic Testing Model for Advanced Prostate Cancer Patients.
Not available
S-EPMC10081955 | biostudies-literature
UnknownCombination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor-Resistant Homologous Recombination-Deficient Ovarian Cancer.
Not available
S-EPMC11934101 | biostudies-literature
Sort   by:  
 Page size